Le Centre Hospitalier de Lens, dit "Dʳ Ernest Schaffner" est un établissement de soin situé au cœur de l'agglomération Lens-Liévin. Il a été certifié par la Haute Autorité de Santé pour 4 ans en 2016. C’est l’hôpital le plus important du Pas-de-Calais en termes d’activité et d'effectifs.

During the past decade, CH LENS conducted 42 clinical trials. In the 10-year time frame, 42 clinical trials started and 6 clinical trials were completed, i.e. on average, 14.3% percent of trials that started reached the finish line to date. In the past 5 years, 20 clinical trials started and 4 clinical trials were completed. i.e. 20% of trials that started reached the finish line.

Out of the total clinical trials conducted in "CH LENS" #1 sponsor was "University Hospital, Lille" with 18 trials, followed by "Acute Leukemia French Association" with 4 trials sponsored, "Centre Hospitalier de Lens" with 3 trials sponsored, "Centre Oscar Lambret" with 3 trials sponsored and "Groupe Francophone des Myelodysplasies" with 3 trials sponsored. Other sponsors include 35 different institutions and companies that sponsored additional 39 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "CH LENS" #1 collaborator was "Ministry of Health, France" with 6 trials as a collaborator, "Amgen" with 2 trials as a collaborator, "Assistance Publique - Hôpitaux de Paris" with 2 trials as a collaborator, "Celgene" with 2 trials as a collaborator and "Celgene Corporation" with 2 trials as a collaborator. Other collaborators include 29 different institutions and companies that were collaborators in the rest 37 trials.

According to Clinical.Site data, the most researched conditions in "CH LENS" are "Acute Myeloid Leukemia" (7 trials), "Critical Illness" (4 trials), "Acute Myeloid Leukemia (AML)" (2 trials), "Alcoholic Hepatitis" (2 trials) and "Covid19" (2 trials). Many other conditions were trialed in "CH LENS" in a lesser frequency.

Most popular intervention types in "CH LENS" are "Drug" (32 trials), "Other" (13 trials), "Device" (6 trials), "Procedure" (6 trials) and "Biological" (4 trials). Other intervention types were less common.

The name of intervention was led by "placebo" (3 trials), "Placebo" (2 trials), "ABVD regimen" (1 trials), "AG-120" (1 trials) and "AG-221" (1 trials). Other intervention names were less common.

The vast majority of trials in "CH LENS" are 69 trials for "All" genders and 2 trials for "Female" genders.

Currently, there are NaN active trials in "CH LENS". 1 are not yet recruiting, 14 are recruiting, 3 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 39 completed trials in CH LENS, undefined suspended trials, and 9 terminated clinical trials to date.

Out of the total trials that were conducted in CH LENS, 1 "Phase 1" clinical trials were conducted, 15 "Phase 2" clinical trials and 18 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 3 trials, and there were also 19 trials that are defined as “Not Applicable".